Katherine Stueland is a visionary healthcare executive and board member recognized for transforming precision medicine and advancing patient advocacy. With over 20 years of leadership experience, she has scaled biotech companies, guided groundbreaking FDA approvals, and driven commercial growth in diagnostics and therapeutics. As CEO of GeneDx, she has tripled sequencing capacity, advanced genomic insights for rare diseases, and positioned the company as a leader in precision medicine. Named to the 2025 CNBC Changemakers list and Fast Company’s Most Innovative Companies, Katherine continues to shape the future of healthcare through innovation, patient-centric strategies, and global impact.